337 related articles for article (PubMed ID: 17477764)
1. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
[TBL] [Abstract][Full Text] [Related]
2. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Naito S; Chang SJ; Chen KK; Cheng C; Choi HY; Fujioka T; Hinotsu S; Hirao Y; Hong SJ; Kim CS; Kim WJ; Lee SE; Murai M; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Xia S; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1285-95. PubMed ID: 15332559
[TBL] [Abstract][Full Text] [Related]
3. Asian trends in prostate cancer hormone therapy.
Akaza H; Naito S; Cheng C; Kaisary A; Soebadi DM; Umbas R; Esuvaranathan K; Gu FL; Zhou L; Hong SJ; Kim WJ; Lee SE; Rim JS; Song JM; Yoon JH; Chang SJ; Huang CH; Yang CR; Hirao Y; Murai M; Tsukamoto T; Usami M
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1951-61. PubMed ID: 12465395
[TBL] [Abstract][Full Text] [Related]
4. The 2nd conference on Asian trends in prostate cancer hormone therapy.
Akaza H; Chang SJ; Chen KK; Esuvaranathan K; Fujioka T; Hirao Y; Hong SJ; Hinotsu S; Kim WJ; Lau W; Lee SE; Murai M; Naito S; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1533-42. PubMed ID: 14584292
[TBL] [Abstract][Full Text] [Related]
5. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
7. Significance of UICC Activities in Global Health Initiatives on Cancer Looking Towards the Future of Cooperative Networks for Cancer Care in Asia - A Dialogue with the Union for International Cancer Control(UICC).
Kawahara N; Adams C; Akaza H
Gan To Kagaku Ryoho; 2017 Sep; 44(9):757-761. PubMed ID: 28912404
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
10. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Chiong E; Murphy DG; Akaza H; Buchan NC; Chung BH; Kanesvaran R; Khochikar M; Letran J; Lojanapiwat B; Ng CF; Ong T; Pu YS; Saad M; Schubach K; Türkeri L; Umbas R; Le Chuyen V; Williams S; Ye DW; ; Davis ID
BJU Int; 2019 Jan; 123(1):22-34. PubMed ID: 30019467
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
16. Secondary hormonal manipulation of prostate cancer.
Small EJ; Harris KA
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):24-30. PubMed ID: 12198635
[TBL] [Abstract][Full Text] [Related]
17. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
18. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
19. Roundtable discussion at the UICC World Cancer Congress: looking toward the realization of universal health coverage for cancer in Asia.
Akaza H; Kawahara N; Nozaki S; Sonoda S; Fukuda T; Cazap E; Trimble EL; Roh JK; Hao X
Asian Pac J Cancer Prev; 2015; 16(1):1-8. PubMed ID: 25640335
[TBL] [Abstract][Full Text] [Related]
20. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
